These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26019274)

  • 1. Photosensitizer and Light Pave the Way for Cytosolic Targeting and Generation of Cytosolic CD8 T Cells Using PLGA Vaccine Particles.
    Bruno C; Waeckerle-Men Y; Håkerud M; Kündig TM; Gander B; Johansen P
    J Immunol; 2015 Jul; 195(1):166-73. PubMed ID: 26019274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes.
    Hjálmsdóttir Á; Bühler C; Vonwil V; Roveri M; Håkerud M; Wäckerle-Men Y; Gander B; Johansen P
    Mol Pharm; 2016 Feb; 13(2):320-9. PubMed ID: 26704885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen.
    Håkerud M; Waeckerle-Men Y; Selbo PK; Kündig TM; Høgset A; Johansen P
    J Control Release; 2014 Jan; 174():143-50. PubMed ID: 24280261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells.
    Håkerud M; Selbo PK; Waeckerle-Men Y; Contassot E; Dziunycz P; Kündig TM; Høgset A; Johansen P
    J Control Release; 2015 Jan; 198():10-7. PubMed ID: 25482339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
    Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
    J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation.
    Silva AL; Rosalia RA; Varypataki E; Sibuea S; Ossendorp F; Jiskoot W
    Vaccine; 2015 Feb; 33(7):847-54. PubMed ID: 25576216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
    Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
    J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photochemically-Mediated Inflammation and Cross-Presentation of
    Waeckerle-Men Y; Kotkowska ZK; Bono G; Duda A; Kolm I; Varypataki EM; Amstutz B; Meuli M; Høgset A; Kündig TM; Halin C; Sander P; Johansen P
    Front Immunol; 2022; 13():815609. PubMed ID: 35173729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses.
    Waeckerle-Men Y; Mauracher A; Håkerud M; Mohanan D; Kündig TM; Høgset A; Johansen P
    Eur J Pharm Biopharm; 2013 Sep; 85(1):34-41. PubMed ID: 23461859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-derived exosomes need to activate both T and B cells to induce antitumor immunity.
    Näslund TI; Gehrmann U; Qazi KR; Karlsson MC; Gabrielsson S
    J Immunol; 2013 Mar; 190(6):2712-9. PubMed ID: 23418627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
    Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
    ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
    Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
    Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
    Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
    J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.